

miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNA^{∇†}

Deo Prakash Pandey and Didier Picard*

Département de Biologie Cellulaire, Université de Genève, Sciences III, 30, quai Ernest-Ansermet, CH-1211 Geneva 4, Switzerland

Received 10 December 2008/Returned for modification 28 January 2009/Accepted 24 April 2009

Estrogen receptor α (ER α) is a ligand-regulated transcription factor with a broad range of physiological functions and one of the most important classifiers in breast cancer. MicroRNAs (miRNAs) are small noncoding RNAs that have emerged as important regulators of gene expression in a plethora of physiological and pathological processes. Upon binding the 3' untranslated region (UTR) of target mRNAs, miRNAs typically reduce their stability and/or translation. The ER α mRNA has a long 3' UTR of about 4.3 kb which has been reported to reduce mRNA stability and which bears evolutionarily conserved miRNA target sites, suggesting that it might be regulated by miRNAs. We have performed a comprehensive and systematic assessment of the regulatory role of all miRNAs that are predicted to target the 3' UTR of the ER α mRNA. We found that miR-22 represses ER α expression most strongly and by directly targeting the ER α mRNA 3' UTR. Of the three predicted miR-22 target sites in the 3' UTR, the evolutionarily conserved one is the primary target. miR-22 overexpression leads to a reduction of ER α levels, at least in part by inducing mRNA degradation, and compromises estrogen signaling, as exemplified by its inhibitory impact on the ER α -dependent proliferation of breast cancer cells.

The steroid hormone 17 β -estradiol (E2) regulates a number of developmental and physiological processes, such as growth and differentiation, in a range of tissues, including the male and female reproductive tracts, breast epithelium, and a plethora of other organs (9, 23). These physiological effects are mediated, at least in part, by two nuclear receptors, estrogen receptor α (ER α) and ER β . Upon binding E2, they are activated as transcription factors and regulate target genes by binding directly to specific regulatory sequences or indirectly to other DNA-bound transcription factors (23). In addition, rapid nongenomic effects of E2 can be elicited by the same ERs as membrane-associated receptors (22). ER α is the more widely expressed of the two ER isoforms, and its levels are regulated by multiple mechanisms in a development- and tissue-specific manner (23). ER α levels are regulated at all levels of gene expression, beginning with transcriptional control by several transcription factors (48) and continuing with regulation at the posttranscriptional (26, 27) and posttranslational levels (2), including the control of protein turnover (44).

Breast cancer is the most frequent form of cancer in women, and ER α is still the most important classifier of breast tumors. ER α -positive tumors, which represent nearly 70% of all breast tumors, respond to E2 for growth and survival, and consequently, ER α -positive tumors can be inhibited with antiestrogens such as tamoxifen. Why and how most tumors eventually become resistant to antiestrogen therapy and why some tumors do not express ER α from the outset remain hotly debated questions. Multiple mechanisms have been invoked to explain

the loss of ER α from initially ER α -positive breast tumors. These include epigenetic modifications such as the hypermethylation of CpG islands in the 5'-regulatory regions of the ER α gene (19) and/or mutations in the open reading frame of the ER α gene (24).

MicroRNAs (miRNAs) are a new class of small noncoding RNAs, 20 to 25 nucleotides in length, that have been shown to regulate gene expression in many physiological and developmental pathways in a multitude of different organisms (5). According to the September 2008 release of miRBase (<http://microrna.sanger.ac.uk>), the number of human miRNAs is 695 (20), but several studies indicate that the number of human miRNA genes could be well over 1,000 (7, 8). Typically, miRNAs regulate gene expression by lowering protein levels by repressing target mRNA translation and/or by inducing the degradation of the mRNA (17). In metazoans, miRNAs target mRNAs by imperfect complementary base pairing (6, 17, 46), for which the most important requirement is a continuous and perfect base pairing of miRNA nucleotides 2 to 8, known as the seed region, to the 3' untranslated region (UTR) of the target mRNA (21, 38). A few exceptions have been reported in which the miRNA associates with the coding region and/or the 5' UTR of the target mRNA (47). There are different computational approaches to predict the targets of miRNAs, and nearly all of these programs predict that a large number of human genes, possibly one-third of all genes, are targets of miRNAs. These predicted target genes represent a broad diversity of molecular functions and biological processes, including development, differentiation, apoptosis, and proliferation (5, 6, 21, 38). Furthermore, a large number of studies have documented the nearly ubiquitous deregulation of miRNA expression in cancer cells (12, 28, 29, 58). These changes in miRNA expression are highly informative for the classification and prognosis of cancer (12). In addition, altered expression of specific miRNAs has been shown to contribute to tumorigen-

* Corresponding author. Mailing address: Département de Biologie Cellulaire, Université de Genève, Sciences III, 30, quai Ernest-Ansermet, CH-1211 Geneva 4, Switzerland. Phone: 41 22 379 6813. Fax: 41 22 379 6928. E-mail: didier.picard@unige.ch.

† Supplemental material for this article may be found at <http://mcb.asm.org/>.

[∇] Published ahead of print on 4 May 2009.

esis and miRNAs have been shown to function as both tumor suppressors and oncogenes (12).

Despite a growing number of studies documenting the miRNA profiles of breast tumors (3, 12, 28, 29, 51, 57), there have been few attempts, and no comprehensive one, to find a mechanistic link between the deregulation of miRNA expression and estrogen signaling through ER α . The ER α mRNA has a long 3' UTR of about 4.3 kb which has been shown to be involved in regulating mRNA levels of ER α . For example, E2 downregulates ER α levels in human MCF7 breast cancer cells by destabilizing the mRNA through sequences present in the 3' UTR (49) whereas E2 upregulates ER α levels by stabilizing the ER α mRNA in sheep endometrium via the 3' UTR (27). Another study supported a role for the 3' UTR in destabilizing the ER α mRNA. With reporter gene assays, it was found that a 1-kb fragment of the 3' UTR retained the destabilizing activity (32). However, the mechanism through which this fragment or the full-length 3' UTR of the ER α mRNA regulates expression has remained elusive. The large size of the ER α 3' UTR makes it likely that it is a target of miRNAs, and indeed, there are recent reports suggesting that miR-206, miR-221, miR-222, and miR-18a repress ER α expression by targeting the ER α 3' UTR (1, 40, 59). Here, we report a comprehensive and systematic survey of the miRNAs predicted to target the 3' UTR of the ER α mRNA by using two different screening approaches. We found that miR-22 is the miRNA that represses ER α expression most significantly and directly through the 3' UTR and that this leads to a reduction in estrogen signaling.

MATERIALS AND METHODS

Cell culture. HEK 293T and HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) without phenol red and supplemented with 10% fetal calf serum (FCS). MCF7-SH cells, a variant of MCF7 cells which are estrogen independent but ER α dependent (31), were maintained in DMEM without phenol red and supplemented with 10% charcoal-treated FCS.

Plasmids. miRNAs were expressed as short hairpin RNAs (shRNAs) with the vector pRetroSuper (10). Control shRNAs against green fluorescent protein, luciferase, and ER α were expressed in a similar fashion. They contain, respectively, the following sequences that are complementary to the targets: 5'-CGG CAAGCTGACCCTGAAGTTC-3' (15), 5'-CGTACGCGGAATACTTCGA-3' (35), and 5'-TCAAGGACATAACGACTAT-3' (41). To generate the miRNA/shRNA constructs, two complementary oligonucleotides (see Table S1A in the supplemental material) with ends compatible with BglII and XhoI restriction sites were annealed, phosphorylated, and ligated into pRetroSuper. To construct the luciferase reporter plasmids, the full-length ER α 3' UTR and various subfragments thereof were amplified from plasmid pGH-UTR (32) with appropriate primers (see Table S1B in the supplemental material), generating SpeI restriction sites at both ends, and inserted into plasmid pGL3-basic (Promega) at the XbaI site downstream of the luciferase coding region. To introduce the two point mutations in the seed region of the full-length 3' UTR and of subfragment UTR2 of the ER α gene, the QuikChange site-directed mutagenesis method was used (for the oligonucleotides used, see Table S1B in the supplemental material).

Reporter assays. For the luciferase reporter assays, 293T, HepG2, and MCF7-SH cells were seeded into 24-well plates. 293T cells were transfected with 2 ng of cytomegalovirus (CMV)-*Renilla* (Promega), 10 ng of pGL3.3'UTR constructs, and 500 ng of miRNA/shRNA constructs by the calcium phosphate coprecipitation method. HepG2 cells were transfected with 2 ng of CMV-*Renilla*, 10 ng of pGL3.3'UTR constructs, and 20 nM of anti-miR-22 and control oligonucleotides (AM10203 and AM17010, respectively; Ambion) by using Fugene HD (Roche) in accordance with the manufacturer's instructions. 293T and HepG2 cells were harvested at 40 h posttransfection. MCF7-SH cells were transfected with 2 ng of CMV-*Renilla*, 200 ng of the ER reporter XETL (11), and 200 ng of miRNA/shRNA constructs by using Fugene HD. At 12 to 16 h posttransfection, the cells were induced with 100 nM 17 β -estradiol for 24 h before harvesting for luciferase assays. For all cells, luciferase activity was mea-

sured with the Dual-Luciferase reporter system (Promega). Firefly luciferase activities were standardized to the *Renilla* luciferase activities as an internal standard of transfection efficiency. All experiments were carried out with triplicate samples, and the data shown are averages of those triplicate samples.

Production of retroviruses and cells stably expressing miRNA/shRNAs. Retroviruses expressing miRNAs/shRNAs were made as described previously (45). Briefly, 293T were cotransfected with 20 μ g pSuperRetro miRNA/shRNA constructs, 5 μ g VSV-G envelope plasmid pMD2.G, and 10 μ g packaging plasmid pCMV.Gag-Pol (vectors were generously provided by Patrick Salmon, Geneva, Switzerland) in 10-cm plates by the calcium phosphate coprecipitation method. At 16 h posttransfection, the transfected cells were washed with Tris-buffered saline (TBS) and further incubated in regular growth medium. At 24 h later, the medium was collected and used to infect cells. To generate cells stably expressing miRNA/shRNAs, MCF7-SH cells were transfected twice overnight with appropriate retroviral supernatants, washed three times with TBS, and then subjected to selection with 3 μ g/ml puromycin for at least 24 h to eliminate the noninfected cells. To minimize clone-to-clone variations, pools of very large numbers of resistant clones were collected.

Immunoblotting. Cells were collected in ice-cold TBS and resuspended in 20 mM Tris-HCl (pH 8)–100 mM NaCl–10% glycerol–0.1% NP-40–1 mM monovanadate–1 mM dithiothreitol–1 \times protease inhibitors. DNA was sheared by seven or eight passages through a 25-gauge needle. The lysates were cleared by centrifugation at 10,000 rpm for 10 min, and protein concentrations were determined by the Bradford assay (Bio-Rad). Extracts (20 μ g) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane, immunoblotted with primary antibodies, incubated with secondary antibodies, and revealed by chemiluminescence. For ER α , monoclonal antibody ER17 was used at a 1:5,000 dilution, and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), antibody ab8245 (Abcam) was used at a 1:10,000 dilution. Immunoblots were imaged and quantified with the Gene-Gnome (Syngene). The intensity of ER α bands was standardized to the intensity of the GAPDH bands.

Proliferation assays. Twenty thousand MCF7-SH cells stably expressing miRNA/shRNAs were seeded into 12-well plates. On the following day (day 0), the cells were washed with warm TBS and further incubated with DMEM supplemented with 1% charcoal-treated FCS. The medium was changed every third day. The cells were counted on day 6, and the cell counts were normalized to MCF7-SH cells expressing a control shRNA. The experiments were carried out in triplicate with one set of pools of stable transformants.

Quantitative PCR (Q-PCR). Endogenous ER α mRNA and exogenously expressed luciferase mRNA were quantitated by real-time PCR after reverse transcription (for the primers used, see Table S1C in the supplemental material). To assess ER α mRNA levels in MCF7-SH cells stably expressing miR-22, an shRNA directed against the ER α mRNA or a control shRNA, triplicate samples were processed, and since the mRNAs of the housekeeping genes for EEF1A1 and TFRC were found to vary the least across all of the samples, all measurements were normalized to the geometric mean of these two control genes. To quantitate exogenously expressed luciferase mRNA levels, 293T cells were cotransfected in six-well plates in triplicate with 60 ng of the luciferase reporter pGL3.3'UTR (full-length ER α 3' UTR) and 3 μ g of the miRNA/shRNA expression constructs per well by the calcium phosphate coprecipitation method. RNA was extracted at 24 h posttransfection and treated with DNase before Q-PCR analysis. Luciferase mRNA levels were normalized to the mRNA of the puromycin resistance gene carried by the cotransfected miRNA/shRNA constructs.

RESULTS

miRNAs targeting the 3' UTR of the ER α mRNA. To identify the putative miRNAs targeting the 3' UTR of the ER α mRNA, we used the three most widely used computational programs, TargetScan (37), PicTar (34), and miRANDA (30). Only the miRNAs found by all of the programs were considered for further analysis. One criterion to filter the miRNAs identified in silico is the evolutionary conservation of the predicted miRNA target(s) in the 3' UTR (21, 38). Based on the bioinformatic prediction and conservation in mammals, we found that the 3' UTR of the ER α mRNA was predicted to be targeted by 13 miRNAs, as depicted in Fig. 1A. While this work was in progress, another study reported that miR-206




FIG. 2. miR-22 targets the 3' UTR of the ER α mRNA. (A) Detailed view of the conserved target site of miR-22. The target site mutations are boxed and indicated by arrows above the sequence. Details of the mutant miR-22 variants are given below the wild-type sequence, which is in white letters on a black background. (B) miR-22 represses the luciferase activity of the wild-type full-length 3' UTR reporter (wt) but not that of the corresponding reporter with a target site mutation (mut). The graph shows the results obtained with 293T cells cotransfected with the indicated reporter plasmids and miRNA constructs. (C) Subfragment 2 (UTR2) of the 3' UTR of ER α contains the conserved target site of miR-22 and mediates miR-22 repression of

the luciferase reporter genes. Mutant form m2 remained largely competent for repression. Importantly, miR-22-mediated repression of the ER α 3' UTR was abolished when the mRNA target site (site 2) was mutated in the context of either the full-length 3' UTR (Fig. 2B) or subfragment UTR2 (Fig. 2C). Repression of the mutant targets was restored with the miR-22 mutant forms that contained complementary changes (Fig. 2). This time, the nucleotide changed in m2 seemed to be more important. It is worth noting that the pattern of repression by wild-type miR-22 and the rescue of repression by the mutant miR-22 variants are very similar for the full-length 3' UTR and UTR2. Taken together, these results emphasize the specificity of the targeting of the ER α 3' UTR by miR-22. Interestingly, we did not observe any effects of miR-206 in the context of either the full-length 3' UTR of the ER α mRNA or subfragments UTR1 and UTR2 in any of our assays (see Fig. S1 in the supplemental material; Fig. 2B and C).

To address the mechanism of repression, we quantitated the amount of luciferase mRNA of the 3' UTR reporter constructs cotransfected with or without miR-22 by real-time PCR (Fig. 2D). The extent of reduction was comparable to that seen at the level of luciferase enzyme activity and to that obtained with an shRNA targeted against the luciferase mRNA. This result suggests that miR-22 represses through the ER α 3' UTR primarily by inducing the degradation of the target mRNA.

Inhibition of miR-22 derepresses the 3' UTR of the ER α mRNA. Our experiments up to this point involved the overexpression of wild-type and mutant miRNAs. Next, we investigated the effect of inhibiting endogenous miR-22 on ER α 3' UTR function by using the same luciferase reporter system. Since 293T and MCF7 cells, as well as MCF7 derivative MCF7-SH cells, do not express miR-22, we chose human HepG2 hepatoma cells, which do express miR-22 (36, 39; data not shown). We cotransfected HepG2 cells with an anti-miR-22 oligonucleotide and the 3' UTR luciferase reporters. As expected, the anti-miR-22 oligonucleotide derepressed the expression of the luciferase reporters containing the wild-type full-length 3' UTR or the UTR2 subfragment, while there were no significant changes with the reporters containing the full-length 3' UTR or UTR2 with mutations in the miR-22 target sequence (site 2) (Fig. 3).

miR-22 represses estrogen signaling. As mentioned above, our second approach consisted of determining whether the downregulation of endogenous ER α levels by miR-22 has any effect on estrogen signaling mediated by ER α . MCF7-SH cells were cotransfected with an ER-reporter construct and constructs expressing wild-type miR-22 or mutant miR-22 variants. Wild-type miR-22 significantly downregulated the expression of the luciferase reporter, whereas the repression was diminished by the mutant miR-22 variants (Fig. 4). Even though the

the luciferase reporter. The graph shows the same type of experiment as in panel B. Data points are averages of triplicate samples, which were standardized to the values obtained with the control shRNA construct, which were set to 100%. Error bars represent standard deviations. (D) Q-PCR analysis of luciferase mRNA levels of the full-length 3' UTR reporter gene in 293T cells cotransfected with the indicated miRNA/shRNA constructs. Shown are averages of triplicate samples with standard deviations.




FIG. 3. Inhibition of miR-22 derepresses the ER α 3' UTR. The anti-miR-22 oligonucleotide or a control oligonucleotide was cotransfected with the indicated reporters into HepG2 hepatoma cells. The hashed line through the middle of the graph separates the data for the two reporters, and the data for each pair of samples (a given reporter without or with the anti-miR-22 oligonucleotide) were standardized to the control sample, which were arbitrarily set to 1.0. In the case of the UTR2 reporter, the luciferase activities obtained in the transfections with the anti-miR-22 and control oligonucleotides are significantly different ($P < 0.05$), as symbolized by the asterisk. Note that there is no significant difference between the luciferase activities represented by the two rightmost bars. wt, wild type; mut, mutant.

reporter gene activity is not fully restored in the presence of the mutant miR-22 variants, this pattern of repression was similar to the pattern of repression of the full-length 3' UTR and UTR2 luciferase reporters observed in 293T cells.

miR-22 downregulates endogenous ER α protein levels and inhibits the proliferation of MCF7-SH cells. A clear prediction from our experiments is that endogenous ER α protein levels should be regulated by miR-22. In turn, this should affect not only the activity of a transfected reporter gene but also a physiological ER α -dependent function. In order to investigate the effect of miR-22 overexpression on endogenous ER α levels, MCF7-SH cells were transduced with retroviruses expressing miR-22, miR-206, an ER α -specific shRNA, and a control shRNA. As the immunoblot assay in Fig. 5 shows, miR-22 overexpression downregulates ER α protein levels to nearly half of those of cells expressing the control shRNA. This is comparable to the downregulation obtained with the specific shRNA that targeted ER α . Again, no significant changes in ER α levels were observed following miR-206 overexpression (Fig. 5). Moreover, the other miRNAs which repressed the luciferase reporter activities less than miR-22 (see Fig. S1 in the supplemental material), notably, miR-19a and miR-181, did not affect ER α levels (data not shown). As previously observed for the exogenously expressed luciferase reporter mRNA, endogenous ER α mRNA levels were significantly reduced in MCF7-SH cells stably expressing either miR-22 or a specific shRNA (Fig. 5C). Clearly, miR-22-induced degradation of the ER α mRNA accounts for much of the repression, but we cannot exclude the possibility that translational repression contributes to the overall repression of ER α expression.

Since MCF7-SH cells are dependent on ER α for proliferation (31), we determined whether reducing the protein levels




FIG. 4. miR-22 represses estrogen signaling by ER α . Constructs expressing wild-type and mutant versions of miR-22 were cotransfected with the ER α reporter into MCF7-SH cells to assay endogenous ER α activity. The results obtained with an shRNA control were arbitrarily set to 100%.

of ER α by miR-22 affects their proliferation. We did proliferation assays of MCF7-SH cells infected with retroviruses expressing miR-22, the ER α -specific shRNA, and a control shRNA and found that expression of miR-22 impairs the proliferation of MCF7-SH cells to an extent similar to that of the shRNA directed at the ER α mRNA (Fig. 5D). Thus, the effects of miR-22 expression on proliferation correlate with the reduced levels of ER α in miR-22-expressing MCF7-SH cells (Fig. 5A and B).

DISCUSSION

We found that miR-22 represses ER α expression by directly targeting the 3' UTR of the ER α mRNA. To identify miR-22 as a regulator of ER α , we have used two complementary approaches based on luciferase reporters to systematically screen all of the miRNAs that might target the 3' UTR of the ER α mRNA. The first approach explored the ability of a miRNA to inhibit mRNA expression by directly targeting the 3' UTR of the reporter mRNA. In the second approach, we measured the activity of an ER-reporter construct, which reflects the ability of the miRNAs to suppress estrogen signaling by reducing ER α levels. Both approaches identified miR-22 as the strongest repressor (see Fig. S1 in the supplemental material). We confirmed the specificity of the miR-22-mediated repression by mutational analyses and observed that inhibition of miR-22 action derepresses the luciferase reporter with a wild-type ER α 3' UTR but not reporters with mutated target sites. Furthermore, we observed that miR-22 overexpression reduces endogenous ER α protein (and mRNA) levels in MCF7-SH cells, resulting in impaired ER α -dependent proliferation (Fig. 5).

miR-22 has three putative target sites in the ER α 3' UTR, only one of which is conserved among mammals. Although seed pairing involving nucleotides 2 to 8 of the 5' end of the miRNA is the most important determinant to predict miRNA targets, this information is not sufficient to predict the miRNA targets with high confidence. Therefore, nearly all of the bioinformatic resources used to predict miRNA targets extensively use the conservation of targets among all mammalian species as a criterion. Perhaps not surprisingly, we found that miR-22




FIG. 5. Overexpression of miR-22 reduces ER α protein levels and inhibits the proliferation of ER α -dependent MCF7-SH cells. (A) Representative immunoblot analysis of ER α for MCF7-SH transformants stably expressing the indicated miRNA/shRNA. The GAPDH immunoblot is shown as a loading control. (B) Quantitation of ER α protein levels. The data shown represent five independent experiments (that is, five independent pools of stable transformants each). Averages, standardized to GAPDH and the control shRNA samples (set to 100%), are shown with error bars indicating standard deviations. Double asterisks indicate values that are significantly different from those of the control shRNA samples ($P < 0.01$), while triple asterisks indicate a significant difference between the values obtained with the miR-22- and miR-206-expressing cell lines ($P < 0.001$). (C) Quantitation of ER α mRNA levels in corresponding stable transformants. Shown are averages of triplicate samples with standard deviations. (D) Proliferation assay of MCF7-SH cells stably expressing miR-22, ER α shRNA, and the control shRNA. Shown are averages of triplicate samples with standard deviations.

targets the ER α 3' UTR through the single conserved site in subfragment UTR2 (Fig. 1, 2, and 4). An earlier study, performed before miRNAs were recognized as important regulators, reported that nearly the same 1-kb region as UTR2 retains the ability of the full-length 3' UTR of ER α to destabilize a reporter mRNA (32). However, at the time, the factors mediating this inhibitory effect could not be identified. Our data provide an explanation of the role of UTR2 in conferring mRNA instability by the 3' UTR of ER α and argue that inhibition is mediated, at least in part, by miR-22.

Recently, several miRNA profiling studies have been performed with breast tumors and/or breast cancer cell lines to understand the role of deregulation of miRNA expression in the development and regulation of breast cancer (3, 12, 28, 29, 51). Some reports have sought to correlate miRNAs levels with ER α status. miR-206, miR-221, and miR-222 appeared to be upregulated in ER α -negative breast tumors and cell lines (1, 33, 59) and repress ER α expression (1, 59). In contrast to these publications, we were not able to observe the repression of any of the 3' UTR reporters by miR-206, nor did miR-206 overexpression significantly downregulate the protein levels of endogenous ER α in MCF7-SH cells. Furthermore, Adams et al. (1) reported that the inhibition of miR-206 upregulates ER α protein levels in a nearly linear and dose-dependent manner in MCF7 cells, which is somewhat puzzling since MCF7 cells, like the MCF7-SH cells derived from them (data not shown), do not even express miR-206 (36). A very recently published analysis of the relationship between miRNA expression profiles and ER α levels in hepatocellular carcinoma cells also failed to find a correlation with miR-206 levels (40). However, the same study did highlight miR-18a, which had also scored positive in our survey with the luciferase reporter gene (see Fig. S1A in the supplemental material) as a regulator of ER α levels both in hepatocellular carcinoma cells and in MCF7 cells. It will be interesting to determine the combinatorial effects of miR-18a and miR-22, whose target sites are in the same region of the ER α 3' UTR (Fig. 1A).

Two very recent reports have suggested that the two closely related miRNAs miR-221 and miR-222 might be involved in conferring tamoxifen resistance on breast cancer cells (43, 59). miR-221/222, which is upregulated in tamoxifen-resistant MCF7 cells compared to tamoxifen-sensitive ones, confers tamoxifen resistance by targeting the cell cycle inhibitor p27/Kip1 (43). miR-221/222 levels are also elevated in ER α -negative breast cancer cell lines (59). Furthermore, the same report indicated that miR-221/222 might confer tamoxifen resistance by directly targeting the ER α mRNA (59). In contrast, we have observed that the miRNAs miR-219 and miR-221/222 upregulate both the ER α 3' UTR reporter and the standard ER α -reporter (see Fig. S1 in the supplemental material). Several recent studies have shown that miRNAs can upregulate gene expression by targeting the promoter (47) or the 3' UTR of the target gene (55, 56). Therefore, it is conceivable that miRNA-219 and/or miR-221/222 upregulate ER α expression by targeting the ER α 3' UTR. Our ongoing investigations are aimed at clarifying the mechanism of these effects and its relevance to the aforementioned correlations between miR-221/222 expression profiles and estrogen signaling. We are at a loss to explain why we did not see repression of ER α expression by miR-206 and miR-221/222. Although we have used slightly different

assays and cell lines, it is difficult to explain these apparent discrepancies. An attractive speculation is that subtle cell-intrinsic or -extrinsic parameters not only affect the overall miRNA complement but also the regulatory impact of individual miRNAs.

There is little information about other genes targeted by miR-22, and only very recently have some miRNA profiling studies shed light on the probable functions of miR-22. Whether miR-22 regulates the expression of other nuclear receptors remains to be seen, but it is unlikely that it affects the expression of the other ER isoform, ER β , since the comparatively short ER β 3' UTR does not contain a recognizable miR-22 target site. miR-22 is part of a set of miRNAs which are significantly more highly expressed in ErbB2-negative breast tumors than in ErbB2-positive ones, in ER α -positive tumors than in ER α -negative ones, and in tumors positive for progesterone receptor than in progesterone receptor-negative ones (42). Yet other studies involving miRNA expression profiling with similar samples did not notice anything with regard to miR-22 (51). Another miRNA profiling study has reported that curcumin, a naturally occurring flavonoid and proapoptotic compound derived from the rhizome of *Curcuma longa*, upregulates miR-22 expression in human pancreatic cells (54). The same authors predicted the ER α mRNA as a target and demonstrated that the transfection of miR-22 mimetics into BxBC-3 pancreatic cancer cells repressed ER α expression. However, the molecular mechanism of this effect was not further characterized and indirect effects could not be ruled out.

There is additional circumstantial evidence for a yin-yang relationship between miR-22 and ER α that fits all of these and our own observations. Of six breast cancer cell lines whose miRNA profiles were established as part of a larger effort to characterize the miRNA profiles of the NCI-60 panel of human tumor-derived cell lines, the only two ER α -positive ones had the lowest levels of miR-22 (18). miR-22 was found to be overexpressed in mouse mammary progenitor cells (25), which may not express ER α (52), and the tissues, such as uterus and ovary, which in the mouse express the highest levels of ER α mRNA (9) have the lowest levels of miR-22 expression (36, 39) (see Fig. S3 in the supplemental material). All of this fits well with the hypothesis that genes which are the target of a particular miRNA have evolved to avoid being expressed at the same time and in the same place as the miRNA (16, 53). The oncogenic transcription factor c-Myc directly represses miR-22 expression in both human and mouse lymphomas (14). Since the *c-myc* gene is induced by ER α , ER α , c-Myc, and miR-22 might be part of a regulatory feedback loop. The fact that there is an ER α binding site 25 kb upstream of the miR-22 transcription start site (13) suggests additional regulatory interactions, but it will require further studies to establish whether miR-22 is an estrogen-responsive gene.

In summary, we have shown that miR-22 targets ER α and represses estrogen signaling. Additional miRNAs may contribute individually (see Fig. S1 in the supplemental material) or in combination to the fine-tuning of ER α levels and allow continuous adaptation to a variety of signals. The precise combination of miRNAs that intervene to set ER α levels is likely to depend on the particular cell type and conditions.

ACKNOWLEDGMENTS

We are grateful to F. Gannon and D. Trono for gifts of reagents. We thank Peter Dudek, Julian Pakay, Asvin Lakkaraju, and Jurgi Camblong for critical reading of the manuscript. We are indebted to the team of the genomics platform of the NCCR Frontiers-in-Genetics at the University of Geneva for help with miRNA expression profiling and Q-PCR.

Funding was provided by the Fondation Medic, the Swiss National Science Foundation, and the Canton de Genève.

REFERENCES

- Adams, B. D., H. Furneaux, and B. A. White. 2007. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor- α (ER α) and represses ER α messenger RNA and protein expression in breast cancer cell lines. *Mol. Endocrinol.* **21**:1132–1147.
- Ali, S., and R. C. Coombes. 2002. Endocrine-responsive breast cancer and strategies for combating resistance. *Nat. Rev. Cancer* **2**:101–112.
- Ambs, S., R. L. Prueitt, M. Yi, R. S. Hudson, T. M. Howe, F. Petrocca, T. A. Wallace, C. G. Liu, S. Volinia, G. A. Calin, H. G. Yfantis, R. M. Stephens, and C. M. Croce. 2008. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Res.* **68**:6162–6170.
- Baek, D., J. Villen, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel. 2008. The impact of microRNAs on protein output. *Nature* **455**:64–71.
- Bartel, D. P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* **116**:281–297.
- Bartel, D. P. 2009. MicroRNAs: target recognition and regulatory functions. *Cell* **136**:215–233.
- Bentwich, I., A. Avniel, Y. Karov, R. Aharonov, S. Gilad, O. Barad, A. Barzilai, P. Einat, U. Einav, E. Meiri, E. Sharon, Y. Spector, and Z. Bentwich. 2005. Identification of hundreds of conserved and nonconserved human microRNAs. *Nat. Genet.* **37**:766–770.
- Berezikov, E., V. Guryev, J. van de Belt, E. Wienholds, R. H. Plasterk, and E. Cuppen. 2005. Phylogenetic shadowing and computational identification of human microRNA genes. *Cell* **120**:21–24.
- Bookout, A. L., Y. Jeong, M. Downes, R. T. Yu, R. M. Evans, and D. J. Mangelsdorf. 2006. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. *Cell* **126**:789–799.
- Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**:550–553.
- Bunone, G., P.-A. Briand, R. J. Miksicek, and D. Picard. 1996. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. *EMBO J.* **15**:2174–2183.
- Calin, G. A., and C. M. Croce. 2006. MicroRNA signatures in human cancers. *Nat. Rev. Cancer* **6**:857–866.
- Carroll, J. S., C. A. Meyer, J. Song, W. Li, T. R. Geistlinger, J. Eeckhoutte, A. S. Brodsky, E. K. Keeton, K. C. Fertuck, G. F. Hall, Q. Wang, S. Bekiranov, V. Sementchenko, E. A. Fox, P. A. Silver, T. R. Gingeras, X. S. Liu, and M. Brown. 2006. Genome-wide analysis of estrogen receptor binding sites. *Nat. Genet.* **38**:1289–1297.
- Chang, T. C., D. Yu, Y. S. Lee, E. A. Wentzel, D. E. Arking, K. M. West, C. V. Dang, A. Thomas-Tikhonenko, and J. T. Mendell. 2008. Widespread microRNA repression by Myc contributes to tumorigenesis. *Nat. Genet.* **40**:43–50.
- Donzé, O., and D. Picard. 2002. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. *Nucleic Acids Res.* **30**:e46.
- Farh, K. K., A. Grimson, C. Jan, B. P. Lewis, W. K. Johnston, L. P. Lim, C. B. Burge, and D. P. Bartel. 2005. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. *Science* **310**:1817–1821.
- Filipowicz, W., S. N. Bhattacharyya, and N. Sonenberg. 2008. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat. Rev. Genet.* **9**:102–114.
- Gaur, A., D. A. Jewell, Y. Liang, D. Ridzon, J. H. Moore, C. Chen, V. R. Ambros, and M. A. Israel. 2007. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. *Cancer Res.* **67**:2456–2468.
- Giacinti, L., P. P. Claudio, M. Lopez, and A. Giordano. 2006. Epigenetic information and estrogen receptor alpha expression in breast cancer. *Oncologist* **11**:1–8.
- Griffiths-Jones, S., H. K. Saini, S. van Dongen, and A. J. Enright. 2008. miRBase: tools for microRNA genomics. *Nucleic Acids Res.* **36**:D154–D158.
- Grimson, A., K. K. Farh, W. K. Johnston, P. Garrett-Engle, L. P. Lim, and D. P. Bartel. 2007. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol. Cell* **27**:91–105.
- Hammes, S. R., and E. R. Levin. 2007. Extracellular steroid receptors: nature and actions. *Endocr. Rev.* **28**:726–741.
- Heldring, N., A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, and J.-Å. Gustafsson. 2007.

- Estrogen receptors: how do they signal and what are their targets. *Physiol. Rev.* **87**:905–931.
24. **Herynk, M. H., and S. A. Fuqua.** 2007. Estrogen receptors in resistance to hormone therapy. *Adv. Exp. Med. Biol.* **608**:130–143.
 25. **Ibarra, I., Y. Erlich, S. K. Muthuswamy, R. Sachidanandam, and G. J. Hannon.** 2007. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. *Genes Dev.* **21**:3238–3243.
 26. **Ing, N. H.** 2005. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. *Biol. Reprod.* **72**:1290–1296.
 27. **Ing, N. H., D. A. Massuto, and L. A. Jaeger.** 2008. Estradiol up-regulates AUF1p45 binding to stabilizing regions within the 3'-untranslated region of estrogen receptor α mRNA. *J. Biol. Chem.* **283**:1764–1772.
 28. **Iorio, M. V., M. Ferracin, C. G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri, M. Campiglio, S. Menard, J. P. Palazzo, A. Rosenberg, P. Musiani, S. Volinia, I. Nenci, G. A. Calin, P. Querzoli, M. Negrini, and C. M. Croce.** 2005. MicroRNA gene expression deregulation in human breast cancer. *Cancer Res.* **65**:7065–7070.
 29. **Iorio, M. V., R. Visone, G. Di Leva, V. Donati, F. Petrocca, P. Casalini, C. Taccioli, S. Volinia, C. G. Liu, H. Alder, G. A. Calin, S. Menard, and C. M. Croce.** 2007. MicroRNA signatures in human ovarian cancer. *Cancer Res.* **67**:8699–8707.
 30. **John, B., A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks.** 2004. Human MicroRNA targets. *PLoS Biol.* **2**:e363.
 31. **Kalkhoven, E., E. Beraldi, M. L. Panno, J. P. De Winter, J. H. Thijssen, and B. Van Der Burg.** 1996. Growth inhibition by anti-estrogens and progestins in TGF- β -resistant and -sensitive breast-tumor cells. *Int. J. Cancer* **65**:682–687.
 32. **Kenealy, M. R., G. Flouriot, V. Sonntag-Buck, T. Dandekar, H. Brand, and F. Gannon.** 2000. The 3'-untranslated region of the human estrogen receptor α gene mediates rapid messenger ribonucleic acid turnover. *Endocrinology* **141**:2805–2813.
 33. **Kondo, N., T. Toyama, H. Sugiura, Y. Fujii, and H. Yamashita.** 2008. miR-206 expression is down-regulated in estrogen receptor α -positive human breast cancer. *Cancer Res.* **68**:5004–5008.
 34. **Krek, A., D. Grun, M. N. Poy, R. Wolf, L. Rosenberg, E. J. Epstein, P. MacMenamin, I. da Piedade, K. C. Gunsalus, M. Stoffel, and N. Rajewsky.** 2005. Combinatorial microRNA target predictions. *Nat. Genet.* **37**:495–500.
 35. **Lakkaraju, A. K., P. P. Luyet, P. Parone, T. Falguieres, and K. Strub.** 2007. Inefficient targeting to the endoplasmic reticulum by the signal recognition particle elicits selective defects in post-ER membrane trafficking. *Exp. Cell Res.* **313**:834–847.
 36. **Landgraf, P., et al.** 2007. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell* **129**:1401–1414.
 37. **Lewis, B. P., C. B. Burge, and D. P. Bartel.** 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**:15–20.
 38. **Lewis, B. P., I. H. Shih, M. W. Jones-Rhoades, D. P. Bartel, and C. B. Burge.** 2003. Prediction of mammalian microRNA targets. *Cell* **115**:787–798.
 39. **Liang, Y., D. Ridzon, L. Wong, and C. Chen.** 2007. Characterization of microRNA expression profiles in normal human tissues. *BMC Genomics* **8**:166.
 40. **Liu, W.-H., S.-H. Yeh, C.-C. Lu, S.-L. Yu, H.-Y. Chen, C.-Y. Lin, D.-S. Chen, and P.-J. Chen.** 2009. microRNA-18a prevents estrogen receptor- α expression, promoting proliferation of hepatocellular carcinoma cells. *Gastroenterology* **136**:683–693.
 41. **Matthews, J., B. Wihlen, J. Thomsen, and J.-Å. Gustafsson.** 2005. Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor α to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-responsive promoters. *Mol. Cell. Biol.* **25**:5317–5328.
 42. **Mattie, M. D., C. C. Benz, J. Bowers, K. Sensinger, L. Wong, G. K. Scott, V. Fedele, D. Ginzinger, R. Getts, and C. Haqq.** 2006. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. *Mol. Cancer* **5**:24.
 43. **Miller, T. E., K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C. L. Shapiro, S. Jacob, and S. Majumder.** 2008. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J. Biol. Chem.* **283**:29897–29903.
 44. **Nawaz, Z., D. M. Lonard, A. P. Dennis, C. L. Smith, and B. W. O'Malley.** 1999. Proteasome-dependent degradation of the human estrogen receptor. *Proc. Natl. Acad. Sci. USA* **96**:1858–1862.
 45. **Parone, P. A., D. I. James, S. Da Cruz, Y. Mattenberger, O. Donze, F. Barja, and J. C. Martinou.** 2006. Inhibiting the mitochondrial fission machinery does not prevent Bax/Bak-dependent apoptosis. *Mol. Cell. Biol.* **26**:7397–7408.
 46. **Pillai, R. S., S. N. Bhattacharyya, and W. Filipowicz.** 2007. Repression of protein synthesis by miRNAs: how many mechanisms? *Trends Cell Biol.* **17**:118–126.
 47. **Place, R. F., L. C. Li, D. Pookot, E. J. Noonan, and R. Dahiya.** 2008. MicroRNA-373 induces expression of genes with complementary promoter sequences. *Proc. Natl. Acad. Sci. USA* **105**:1608–1613.
 48. **Reid, G., S. Denger, M. Kos, and F. Gannon.** 2002. Human estrogen receptor- α : regulation by synthesis, modification and degradation. *Cell. Mol. Life Sci.* **59**:821–831.
 49. **Saceda, M., M. E. Lippman, P. Chambon, R. L. Lindsey, M. Ponglikitmongkol, M. Puente, and M. B. Martin.** 1988. Regulation of the estrogen receptor in MCF-7 cells by estradiol. *Mol. Endocrinol.* **2**:1157–1162.
 50. **Selbach, M., B. Schwanhauser, N. Thierfelder, Z. Fang, R. Khanin, and N. Rajewsky.** 2008. Widespread changes in protein synthesis induced by microRNAs. *Nature* **455**:58–63.
 51. **Sempere, L. F., M. Christensen, A. Silahatoglu, M. Bak, C. V. Heath, G. Schwartz, W. Wells, S. Kauppinen, and C. N. Cole.** 2007. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. *Cancer Res.* **67**:11612–11620.
 52. **Sleeman, K. E., H. Kendrick, D. Robertson, C. M. Isacke, A. Ashworth, and M. J. Smalley.** 2007. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. *J. Cell Biol.* **176**:19–26.
 53. **Stark, A., J. Brennecke, N. Bushati, R. B. Russell, and S. M. Cohen.** 2005. Animal microRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. *Cell* **123**:1133–1146.
 54. **Sun, M., Z. Estrov, Y. Ji, K. R. Coombes, D. H. Harris, and R. Kurzrock.** 2008. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. *Mol. Cancer Ther.* **7**:464–473.
 55. **Vasudevan, S., and J. A. Steitz.** 2007. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. *Cell* **128**:1105–1118.
 56. **Vasudevan, S., Y. Tong, and J. A. Steitz.** 2007. Switching from repression to activation: microRNAs can up-regulate translation. *Science* **318**:1931–1934.
 57. **Verghese, E. T., A. M. Hanby, V. Speirs, and T. A. Hughes.** 2008. Small is beautiful: microRNAs and breast cancer—where are we now? *J. Pathol.* **215**:214–221.
 58. **Yanaihara, N., N. Caplen, E. Bowman, M. Seike, K. Kumamoto, M. Yi, R. M. Stephens, A. Okamoto, J. Yokota, T. Tanaka, G. A. Calin, C. G. Liu, C. M. Croce, and C. C. Harris.** 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* **9**:189–198.
 59. **Zhao, J. J., J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola, and J. Q. Cheng.** 2008. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. *J. Biol. Chem.* **283**:31079–31086.

AUTHOR'S CORRECTION

miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNA

Deo Prakash Pandey and Didier Picard

Département de Biologie Cellulaire, Université de Genève, Sciences III, 30, quai Ernest-Ansermet, CH-1211 Geneva 4, Switzerland

Volume 29, no. 13, p. 3783–3790, 2009. After publication, we became aware of some inaccurate and incomplete statements. The conclusions are in no way affected by the additional and corrected information listed below.

Page 3784, column 1, Materials and Methods, paragraph 2, line 10: “the full-length ER α 3' UTR” should read “the ER α 3' UTR (which we will refer to as full length even though it lacked the 5'-most 348 nucleotides out of 4.3 kb).”

Page 3785, column 1, lines 1 to 4: The sentence beginning “Although . . .” should be replaced with the following. “We had initially excluded it from our list of miRNAs because its target sites are not conserved and because TargetScan, even with relaxed search criteria, fails to identify the primary target site located at the very 5' end of the 3' UTR reported in that publication. Hence, the latter is not shown in Fig. 1, which does show two other nonconserved miR-206 sites, and it is not included in our ER α 3' UTR constructs. Nevertheless, we decided to investigate miR-206 in parallel in some of the key experiments.”

Page 3788, column 2, line 22: The following sentence should be added after “in MCF7-SH cells.” “Note that high levels of both miR-22 and miR-206 were reached in transient-transfection experiments with 293T cells (103-fold and 40,258-fold, respectively, compared to a control transfection) and in stable MCF7-SH transformants (levels comparable to those of the endogenous miRNAs let-7i and let-7g) (data not shown).”

Page 3788, column 2, line 24: “protein levels” should read “mRNA levels.”

Page 3788, column 2, lines 25 to 27: “since MCF7 cells . . . express miR-206 (36)” should read “since MCF7-SH cells, derived from MCF7 cells, do not express miR-206 (data not shown) and since another study could not find miR-206 expression in MCF7 cells (36).”